Trial of Influenza A(H1N1) 2009 Monovalent MF59-Adjuvanted Vaccine -- Preliminary Report
This article, published in The New England Journal of Medicine, describes the methods, results, and conclusions from a single-center study to test the monovalent influenza A/California/2009 (H1N1) surface-antigen vaccine. The study, conducted in the United Kingdom, compared both MF59-adjuvanted and nonadjuvanted forms of the vaccine. One hundred and fifty-seven adults participated in the study and received two doses of the vaccine. The authors concluded that a single dose of the MF59-adjuvanted vaccine generated antibody responses likely to provide protection within 14 days.
Author(s): Clark TW, Pareek M, Hoschler K, et al.
Visit web page (English)
(Located at content.nejm.org)
Citation: Clark TW, Pareek M, Hoschler K, et al. Trial of Influenza A(H1N1) 2009 -- Monovalent MF59-Adjuvanted Vaccine -- Preliminary Report. New England Journal of Medicine. 2009. Epub ahead of print.